Share on StockTwits

Enzymotec Ltd (NASDAQ:ENZY) updated its FY14 earnings guidance on Thursday. The company provided EPS guidance of $0.77-0.94 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.76, AR Network reports. The company issued revenue guidance of $88-95 million, compared to the consensus revenue estimate of $92.70 million.

Several analysts have recently commented on the stock. Analysts at Bank of America downgraded shares of Enzymotec to an underperform rating in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $26.33.

Shares of Enzymotec Ltd (NASDAQ:ENZY) remained flat at $25.60 during trading on Thursday. The stock had a trading volume of 65,764 shares. Enzymotec Ltd has a one year low of $14.25 and a one year high of $35.12. The stock’s 50-day moving average is $26.96 and its 200-day moving average is $24.53. The company has a market cap of $551.2 million and a price-to-earnings ratio of 70.14.

Enzymotec (NASDAQ:ENZY) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.15 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.11 by $0.04. The company had revenue of $18.51 million for the quarter, compared to the consensus estimate of $11.64 million. Enzymotec’s revenue was up 59.5% compared to the same quarter last year. Analysts expect that Enzymotec Ltd will post $0.47 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.